Targeting DDX 3 with a small molecule inhibitor for lung cancer therapy
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Lung cancer is the most common malignancy worldwide and is a focus for developing targeted therapies due to its refractory nature to current treatment. We identified a RNA helicase, DDX 3, which is overexpressed in many cancer types including lung cancer and is associated with lower survival in lung cancer patients. We designed a first‐in‐class small molecule inhibitor, RK‐33, which binds to DDX 3 and abrogates its activity. Inhibition of DDX 3 by RK‐33 caused G1 cell cycle arrest, induced apoptosis, and promoted radiation sensitization in DDX 3‐overexpressing cells. Importantly, RK ‐33 in combination with radiation induced tumor regression in multiple mouse models of lung cancer. Mechanistically, loss of DDX 3 function either by sh RNA or by RK ‐33 impaired Wnt signaling through disruption of the DDX 3–β‐catenin axis and inhibited non‐homologous end joining—the major DNA repair pathway in mammalian somatic cells. Overall, inhibition of DDX 3 by RK ‐33 promotes tumor regression, thus providing a compelling argument to develop DDX 3 inhibitors for lung cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A.-P., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01014-0 · Cited by 2,030
Dissecting the genomic complexity underlying medulloblastoma
Jones, D. T. W., Jäger, N., Kool, M., Zichner, T., Hutter, B., Sultan, M., Cho, Y.-J., Pugh, T. J., Hovestadt, V., Stütz, A. M., et al. (2012) · Nature · doi:10.1038/nature11284 · Cited by 839 · cited 1×
“Activating mutations of DDX3 were also shown to be involved in pathogenic Wnt pathway activation in medulloblastoma (Jones et al , 2012; Pugh et al , 2012; Robinson et al , 2012) and chronic lymphatic leukemia (CLL) (Wang et al , 2011).”
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations
Pugh, T. J., Weeraratne, S. D., Archer, T. C., Pomeranz Krummel, D. A., Auclair, D., Bochicchio, J., Carneiro, M. O., Carter, S. L., Cibulskis, K., Erlich, R. L., et al. (2012) · Nature · doi:10.1038/nature11329 · Cited by 750
Cited by
DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome
Samir, P., Kesavardhana, S., Patmore, D. M., Gingras, S., Malireddi, R. K. S., Karki, R., Guy, C. S., Briard, B., Place, D. E., Bhattacharya, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1551-2 · Cited by 413
Cheng, W., Wang, S., Zhang, Z., Morgens, D. W., Hayes, L. R., Lee, S., Portz, B., Xie, Y., Nguyen, B. V., Haney, M. S., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.09.003 · Cited by 138
Dietrich, L., Rathmer, B., Ewan, K., Bange, T., Heinrichs, S., Dale, T. C., Schade, D., & Grossmann, T. N. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.06.013 · Cited by 126
Metadata
- Authors
- Bol, G. M., Vesuna, F., Xie, M., Zeng, J., Aziz, K., Gandhi, N., Levine, A., Irving, A., Korz, D., Tantravedi, S., Heerma van Voss, M. R., Gabrielson, K., Bordt, E. A., Polster, B. M., Cope, L., van der Groep, P., Kondaskar, A., Rudek, M. A., Hosmane, R. S., van der Wall, E., van Diest, P. J., Tran, P. T., & Raman, V.
- Venue
- EMBO Molecular Medicine
- Published
- 2015-03-27
- Volume
- 7
- Issue
- 5
- Pages
- 648-669
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2028342121
- Cited by
- 215
- References
- 5
- FWCI
- 6.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.